CY1119407T1 - Διαμορφωτες toy lxr - Google Patents

Διαμορφωτες toy lxr

Info

Publication number
CY1119407T1
CY1119407T1 CY20171100403T CY171100403T CY1119407T1 CY 1119407 T1 CY1119407 T1 CY 1119407T1 CY 20171100403 T CY20171100403 T CY 20171100403T CY 171100403 T CY171100403 T CY 171100403T CY 1119407 T1 CY1119407 T1 CY 1119407T1
Authority
CY
Cyprus
Prior art keywords
lxr
toy
models
compounds
disclosed
Prior art date
Application number
CY20171100403T
Other languages
English (en)
Inventor
Brett B. Busch
William C. Stevens, Jr.
Ellen K. Kick
Haiying Zhang
Venkataiah Bollu
Richard Martin
Raju Mohan
Original Assignee
Exelixis Patent Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43223342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119407(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Patent Company Llc filed Critical Exelixis Patent Company Llc
Publication of CY1119407T1 publication Critical patent/CY1119407T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ενώσεις, φαρμακευτικώς αποδεκτά άλατα, ισομερή, ή προφάρμακα εξ' αυτών, της εφεύρεσης αποκαλύπτονται, οι (τα) οποίες (-α) είναι χρήσιμες (-α) ως διαμορφωτές της δραστηριότητας των υποδοχέων Χ ήπατος (LXR). Φαρμακευτικές συνθέσεις που περιέχουν τις ενώσεις και μέθοδοι χρήσης των ενώσεων αποκαλύπτονται επίσης.
CY20171100403T 2009-05-28 2017-04-05 Διαμορφωτες toy lxr CY1119407T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18173609P 2009-05-28 2009-05-28
PCT/US2010/036211 WO2010138598A2 (en) 2009-05-28 2010-05-26 Lxr modulators

Publications (1)

Publication Number Publication Date
CY1119407T1 true CY1119407T1 (el) 2018-03-07

Family

ID=43223342

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100403T CY1119407T1 (el) 2009-05-28 2017-04-05 Διαμορφωτες toy lxr

Country Status (30)

Country Link
US (4) US8618154B2 (el)
EP (1) EP2435410B1 (el)
JP (1) JP5625050B2 (el)
KR (1) KR101676704B1 (el)
CN (1) CN102648184B (el)
AR (1) AR078049A1 (el)
AU (1) AU2010254082B2 (el)
BR (1) BRPI1013259B8 (el)
CA (1) CA2761934C (el)
CL (1) CL2011002972A1 (el)
CO (1) CO6470826A2 (el)
CY (1) CY1119407T1 (el)
DK (1) DK2435410T3 (el)
EA (1) EA019960B1 (el)
ES (1) ES2620451T3 (el)
HR (1) HRP20170194T1 (el)
IL (1) IL216176A (el)
LT (1) LT2435410T (el)
MX (1) MX2011012559A (el)
MY (1) MY153958A (el)
NZ (1) NZ596330A (el)
PE (1) PE20120797A1 (el)
PL (1) PL2435410T3 (el)
PT (1) PT2435410T (el)
SG (1) SG176247A1 (el)
SI (1) SI2435410T1 (el)
TN (1) TN2011000585A1 (el)
TW (1) TWI488844B (el)
WO (1) WO2010138598A2 (el)
ZA (1) ZA201108181B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120797A1 (es) * 2009-05-28 2012-07-08 Exelisis Patent Company Llc Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
TW201242953A (en) * 2011-03-25 2012-11-01 Bristol Myers Squibb Co Imidazole prodrug LXR modulators
AU2013225840B2 (en) 2012-03-02 2017-11-23 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
WO2014028461A2 (en) * 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
WO2014152738A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
EP2968275B1 (en) * 2013-03-15 2017-11-29 Bristol-Myers Squibb Company Lxr modulators
JP2016532713A (ja) 2013-09-04 2016-10-20 アレクサー セラピューティクス， インク． 肝臓ｘ受容体（ｌｘｒ）調節因子
RS60479B1 (sr) 2013-09-04 2020-08-31 Ellora Therapeutics Inc Modulatori receptora x jetre (lxr)
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
KR101815734B1 (ko) 2015-05-29 2018-01-05 가톨릭대학교 산학협력단 ｍｉＲ－７, ｍｉＲ－１８ａ 또는 ｍｉＲ－１８ｂ를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물
CN109069461A (zh) 2016-01-11 2018-12-21 洛克菲勒大学 与髓源性抑制细胞相关的病症的治疗方法
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
JP2022541013A (ja) 2019-07-15 2022-09-21 ノバルティス アーゲー 肝臓ｘ受容体アゴニストでマイボーム腺機能不全を治療するための方法
CN110305141B (zh) * 2019-07-18 2022-01-11 深圳市三启药物开发有限公司 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
AU2579692A (en) 1991-09-17 1993-04-27 Salk Institute For Biological Studies, The Receptor of the thyroid/steroid hormone receptor superfamily
JP2001509165A (ja) 1997-01-24 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア バリヤ機能の回復、表皮の分化の促進及び増殖の抑制のためのＦＸＲ、ＰＰＡＲα及びＬＸＲαの活性剤の使用
AU5994199A (en) 1998-09-23 2000-04-10 Alexander Mata De Urquiza Analysis of ligand activated nuclear receptors (in vivo)
US6639078B1 (en) 1998-12-23 2003-10-28 Smithkline Beecham Corporation Assays for ligands for nuclear receptors
DE60013417T2 (de) 1999-03-26 2005-09-15 City Of Hope, Duarte Verfahren zum screenen von fxr-rezeptormodulatoren
CA2375787C (en) 1999-06-18 2007-03-27 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
US20020048572A1 (en) 2000-05-03 2002-04-25 Bei Shan Treatment of hypertriglyceridemia and other conditions using LXR modulators
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
US7109227B2 (en) * 2002-08-26 2006-09-19 National Health Research Institutes Imidazolamino compounds
US7534805B2 (en) * 2003-05-27 2009-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Imidazole derivatives, their preparation and their use as medicaments
WO2005047266A1 (en) * 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
US8158662B2 (en) * 2004-02-11 2012-04-17 Hamilton Compounds and compositions as LXR modulators
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
WO2007002563A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
US7998995B2 (en) * 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
PE20120797A1 (es) * 2009-05-28 2012-07-08 Exelisis Patent Company Llc Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr

Also Published As

Publication number Publication date
US8618154B2 (en) 2013-12-31
BRPI1013259A2 (pt) 2016-04-05
EA201171488A1 (ru) 2012-07-30
IL216176A (en) 2015-10-29
CN102648184B (zh) 2015-09-30
AR078049A1 (es) 2011-10-12
CA2761934A1 (en) 2010-12-02
AU2010254082B2 (en) 2015-01-29
KR101676704B1 (ko) 2016-11-16
WO2010138598A2 (en) 2010-12-02
NZ596330A (en) 2013-07-26
CN102648184A (zh) 2012-08-22
US20120071534A1 (en) 2012-03-22
TW201109308A (en) 2011-03-16
BRPI1013259B1 (pt) 2021-04-13
ES2620451T3 (es) 2017-06-28
LT2435410T (lt) 2017-04-10
EA019960B1 (ru) 2014-07-30
JP2012528180A (ja) 2012-11-12
TN2011000585A1 (en) 2013-05-24
US20150299136A1 (en) 2015-10-22
SG176247A1 (en) 2012-01-30
TWI488844B (zh) 2015-06-21
HRP20170194T1 (hr) 2017-05-19
WO2010138598A3 (en) 2011-07-28
EP2435410B1 (en) 2017-01-18
JP5625050B2 (ja) 2014-11-12
ZA201108181B (en) 2013-01-30
US20140163081A1 (en) 2014-06-12
MX2011012559A (es) 2012-06-08
PE20120797A1 (es) 2012-07-08
DK2435410T3 (da) 2017-04-10
MY153958A (en) 2015-04-30
PL2435410T3 (pl) 2017-07-31
AU2010254082A1 (en) 2011-12-08
PT2435410T (pt) 2017-05-03
BRPI1013259B8 (pt) 2021-05-25
EP2435410A2 (en) 2012-04-04
CA2761934C (en) 2018-01-09
IL216176A0 (en) 2012-01-31
SI2435410T1 (sl) 2017-06-30
KR20120047868A (ko) 2012-05-14
CL2011002972A1 (es) 2012-08-17
US20160280661A1 (en) 2016-09-29
CO6470826A2 (es) 2012-06-29

Similar Documents

Publication Publication Date Title
CY1119407T1 (el) Διαμορφωτες toy lxr
CY1119177T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
CY1118819T1 (el) Ετεροκυκλικες ενωσεις αγωνιστες του υποδοχεα ip
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
CY1118915T1 (el) Αντιβακτηριακα αναλογα αμινογλυκοσιδης
CY1115426T1 (el) 1,3-δισυποκατεστημενα παραγωγα ιμιδαζολιδιν-2-ονης ως αναστολεις toy cyp 17
CY1110221T1 (el) Σταθερα φαρμακευτικα σκευασματα νατριουχου μοντελουκαστης
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
SG162804A1 (en) Pyrazole based lxr modulators
CY1116927T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
CY1115176T1 (el) Ρυθμιστες υποδοχεων τυπου toll
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
UY30460A1 (es) Compuestos terapéuticos
CR11819A (es) Compuestos de isoindolina 5-sustituidos
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
CY1112860T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1110990T1 (el) Παραγωγα αδενοσινης ως αγωνιστες υποδοχεων α2α
UY30977A1 (es) Derivados de isoindolinas 4' -o-sustituidas. composiciones que las contienen y metodos para sus usos.
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
ATE536172T1 (de) Ezetimibzusammensetzungen